Who are TETA 4HCL (W12-60)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cordarone, minoxidil 5% solution, Minoxidil lotion 2%, metformin+ gliclazide, Brinavess (Vernakalant), Sustained-release oral dalfampridine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/teta-4hcl-w12-60.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

TETA 4HCL (W12-60) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

TETA 4HCL (W12-60) (TETA 4HCL (W12-60)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel blocker. Area: Cardiovascular.

phase 3 Potassium channel blocker Potassium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

TETA 4HCL (W12-60) (TETA 4HCL (W12-60)) — Orphalan. TETA 4HCL (W12-60) is a tetraethylammonium chloride, a potassium channel blocker.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
TETA 4HCL (W12-60) TARGET	TETA 4HCL (W12-60)	Orphalan	phase 3	Potassium channel blocker	Potassium channels
Cordarone	AMIODARONE	Pfizer	marketed	Antiarrhythmic	sodium channels, potassium channels, calcium channels	1985-01-01
minoxidil 5% solution	minoxidil 5% solution	Allergan	marketed	Potassium channel opener	ATP-sensitive potassium channels
Minoxidil lotion 2%	Minoxidil lotion 2%	Mae Fah Luang University Hospital	marketed	Potassium channel opener / topical hair growth stimulant	ATP-sensitive potassium channels (KATP); exact follicle-specific target unclear
metformin+ gliclazide	metformin+ gliclazide	GlaxoSmithKline	marketed	Antidiabetic combination (biguanide + sulfonylurea)	Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells
Brinavess (Vernakalant)	Brinavess (Vernakalant)	Medical University of Vienna	marketed	Atrial-selective antiarrhythmic agent	Atrial potassium channels (Kv1.5, Kv4.3) and sodium channels
Sustained-release oral dalfampridine	Sustained-release oral dalfampridine	Sheba Medical Center	marketed	Potassium channel blocker	Voltage-gated potassium channels (Kv channels)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel blocker class)

Orphalan · 3 drugs in this class
Biogen · 2 drugs in this class
Essentialis, Inc. · 1 drug in this class
National Center for Research Resources (NCRR) · 1 drug in this class
Oregon Health and Science University · 1 drug in this class
Sheba Medical Center · 1 drug in this class
University of Southern Denmark · 1 drug in this class
D'Youville College · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). TETA 4HCL (W12-60) — Competitive Intelligence Brief. https://druglandscape.com/ci/teta-4hcl-w12-60. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab